Repeat operative or clinic-based procedures to debulk papillomatous disease have been the standard of care to date in the treatment of patients with recurrent respiratory papillomatosis (RRP) caused by chronic infection with human papillomavirus (HPV) type 6 or 11. Treatment of RRP is one of the rare instances in medicine of a chronic infection treated with repeat procedural intervention.
This consensus statement highlights the importance of consultative discussions with patients with RRP and their caregivers regarding bevacizumab as a possible nonsurgical treatment and outlines numerous specific considerations concerning systemic administration of the drug.
Systemic bevacizumab appears to have significant promise and a low complication profile for the most treatment- resistant and aggressive forms of papillomatosis.
Recurrent respiratory papillomatosis is incurable with current treatment modalities, but adjuvant therapies should be used when surgery cannot control the disease.
In untreated RRP patients presenting to three laryngology clinics, males had more anatomic sites affected by papilloma than females.
What is the prevalence of dysplasia in recurrent respiratory papillomatosis? Background: Recurrent respiratory papillomatosis (RRP) is a debilitating disease caused by the human papilloma virus (HPV). Between two percent and four […]
What is the association between an increasing degree of papilloma dysplasia and the use of cidofovir in the context of the natural progression of dysplasia in recurrent respiratory papillomatosis (RRP)? […]